Effect of Stitch Technique on the Occurrence of Incisional Hernia After Abdominal Wall Closure
Launched by AESCULAP AG · Oct 15, 2013
Trial Information
Current as of May 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years
- • Patients undergoing an elective, primary median laparotomy with an incision length of ≥ 15 cm
- • Expected survival time longer than 1 year
- • ASA I-III
- • Written informed consent
- Exclusion Criteria:
- • Emergency surgery
- • Patient undergoing surgery due to a pancreas carcinoma
- • Patients who will be operated due to an abdominal aortic aneurysm
- • Peritonitis
- • Coagulopathy
- • Current immunosuppressive therapy (more than 40 mg of a corticoid per day or azathioprin)
- • Chemotherapy within the last 2 weeks before operation
- • Radiotherapy of the abdomen within the last 6 weeks before operation
- • Pregnant women (pregnancy test has to be performed)
- • Severe neurologic and psychiatric disease
- • Lack of compliance
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Braunschweig, , Germany
Wien, , Austria
Linz, , Austria
Berlin, , Germany
Frankfurt, , Germany
Göppingen, , Germany
München, , Germany
Stuttgart, , Germany
Tuttlingen, , Germany
Patients applied
Trial Officials
Rene Fortelny, Dr.
Principal Investigator
Wilhelminenspital Wien
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials